Diagnose Early, Stop Progression, Rehabilitate Vision
The new mantra of keratoconic care is: Diagnose early, Stop progression, Rehabilitate vision. Currently, in the stop progression category, there is only 1 FDA approved treatment to stop progression of keratoconus, corneal crosslinking (CXL). News of a potential new treatment would offer another option to stop progression.
In September 2017, a press release regarding the award of an SBIR grant to investigate a topical treatment for keratoconus hit the internet. “iVeena is pleased to receive a total of $450K in Federal Government grants to advance its portfolio programs,” said Gerald Simmons, CEO. “$225K is an NIH grant for its Keratoconus Orphan Drug Candidate. IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea.”
Since the press release, many patients with Keratoconus and many doctors want a better understanding of the treatment and the timeline for its availability. To better understand the treatment, it’s important to understand the SBIR program.
If you would like to read this complete article, please signup as a member!